“The pipeline currently includes tests for psoriatic arthritis (RAPsA Dx), prostate cancer (OCPro Dx) and diabetic kidney disease (ProMarker D),” said Prof Stephen Pennington, founder of Atturos and its chief scientific officer. Atturos is looking to support this revolution with its pipeline of advanced blood tests for a variety of conditions. Personalised medicine is poised to revolutionise healthcare, giving clinicians the ability to prescribe treatment tailored to the individual. “From its start, Atturos has been listening to and working closely with patient representative groups, clinicians and industry to identify the unmet needs where our technology and products will make a significant difference to patient care.”Ī spin-out of University College Dublin (UCD), Atturos combines data science and machine learning analytics with proteomics, the large-scale study of proteins, to deliver what Perryman calls “highly specific, personalised diagnostic information”.

“Our vision is to help patients and doctors with their decision-making,” said Robert Perryman, CEO of Atturos.

This UCD biotech spin-out is combining algorithms and the study of proteins to better detect disease biomarkers in blood samples.

Pacific diagnostics